explore -WSS

explore

author：comprehensive 2025-10-02 21:35:45 - browse：73561

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Brain 'hot spot' may explain why African Americans feel greater pain

WSS

Midwives could help bridge maternal health disparities in the U.S.

A new study asks: Are we harming blood donors by taking blood?

The struggle to figure out which patients 'deserve' Wegovy

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Grail is spending more than ever lobbying Congress

House panel takes first step toward fixing drug shortages

explore

explore

hotspot

Medicare details structure of new drug price negotiation program

Van's Gluten Free Original Waffles recalled for possible wheat allergen

Guidelines to prevent youth baseball injuries need more muscle

David Liu startup to focus on CRISPR delivery

Medicare details structure of new drug price negotiation program

Community addresses injustice for Long Island mothers

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Chamber of Commerce, DOJ clash in court over drug prices

Sports medicine is finally prioritizing gender equality

Information blocking fines are now fair game in health care

focus

Listen: Biogen's messy board & Laronde's data problem

Listen: Biogen's messy board & Laronde's data problem

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

4th of July breaks record for highest global temperature ever measured

David Liu startup to focus on CRISPR delivery

People with substance use disorder deserve online privacy

hotspot

hotspot

focus

leisure time